Providing a VOICE for Wisconsin's MULTIDISCIPLINARY CANCER CARE TEAMs and the PATIENTS THEY SERVE since 1991
Join/Renew
About
About Us
WAHO Leadership
Executive Office
Meetings & Education
Upcoming Events
Virtual Learning
Financial Advocacy & Patient Assistance
Advocacy
WAHO Advocacy
Patient Advocacy Organizations
Resources
State & Federal Resources
Off-Label Use Literature
Find A Clinical Trial
National Professional Organizations
Industry
WAHO Corporate Members
Become a Corporate Member
Exhibitor Information
Industry News Archive
With Project Orbis Collaboration, FDA Approves New Treatment for Endometrial Cancer
On September 17, the U.S. Food and Drug Administration (FDA) announced
Project Orbis
, an initiative of the FDA Oncology Center of Excellence (OCE). Project Orbis provides a framework for concurrent submission and review of oncology drugs among its international partners.
As part of Project Orbis, in conjunction with decisions by the Australian Therapeutic Goods Administration (TGA) and Health Canada, the
FDA today granted accelerated approval to Lenvima (lenvatinib) in combination with Keytruda (pembrolizumab)
for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), and who have disease progression following prior systemic therapy but are not candidates for curative surgery or radiation. Collaboration among international regulators through Project Orbis allowed for simultaneous decisions in all three countries.
Read FDA announcement on Project Orbis
.
Read more on
FDA approval of lenvatinib in combination with pembrolizumab for certain patients with advanced endometrial carcinoma
.
Posted 9/17/2019